HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,844,753 shares, an increase of 573.5% from the April 30th total of 570,862 shares. Based on an average daily volume of 39,013,224 shares, the days-to-cover ratio is presently 0.1 days. Currently, 62.8% of the company’s shares are sold short.
Insider Buying and Selling
In related news, Director Scott T. Garrett purchased 177,936 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was purchased at an average price of $1.41 per share, with a total value of $250,889.76. Following the completion of the transaction, the director owned 203,441 shares of the company’s stock, valued at approximately $286,851.81. This trade represents a 697.65% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.10% of the company’s stock.
Institutional Trading of HCW Biologics
A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent reporting period. Institutional investors and hedge funds own 2.96% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on HCW Biologics
HCW Biologics Price Performance
HCWB stock traded down $0.11 during midday trading on Friday, reaching $1.98. 2,499,032 shares of the company’s stock traded hands, compared to its average volume of 36,336,384. The company has a market capitalization of $13.33 million, a P/E ratio of -0.21 and a beta of 1.13. HCW Biologics has a fifty-two week low of $0.25 and a fifty-two week high of $8.75. The business has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $1.15.
HCW Biologics (NASDAQ:HCWB – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.81. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The company had revenue of $6.54 million during the quarter, compared to the consensus estimate of $6.54 million.
HCW Biologics Company Profile
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Read More
- Five stocks we like better than HCW Biologics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
